Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Precision Bio Shares Phase 1 PBGENE-HBV Trial Data

September 12, 2025

Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases,

Categories

Tag: Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Precision Bio Shares Phase 1 PBGENE-HBV Trial Data

Share With

Recent Posts

Konica Minolta Teams with NewVue for Exa Teleradiology

Fresenius Kabi Nomogram Now Used at BioLife Plasma Centers

Salt AI Adds Biotech and AI Leaders After $10Million Funding

WELL Health Updates on WELLSTAR Growth and Wins

AvantGuard Awarded $2.65 Million in NIH Grants to Advance Next-Generation Antimicrobial Technologies

Quick Links

Insights

Get in touch

Follow Us

Our Other Brands